Added to YB: 2026-09-21
Pitch date: 2026-09-16
RGNX [neutral]
REGENXBIO Inc.
-3.72%
current return
Author Info
No bio for this author
Company Info
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States.
Market Cap
$530.1M
Pitch Price
$8.34
Price Target
N/A
Dividend
N/A
EV/EBITDA
-5.01
P/E
-2.13
EV/Sales
3.87
Sector
Biotechnology
Category
special_situation
Biotech Conferences Week 2 Day 3 Part 1 - REGENXBIO Inc.
RGNX (update): At $7.95, REGENXBIO is a target/partner candidate with a 72 M&A Score and 70 Growth Score ahead of Q4 Phase 3 wet-AMD data for AbbVie-partnered RGX-314 and a late-year RGX-202 pre-BLA meeting. RGX-314 must show BCVA noninferiority and persuasive injection reduction despite delivery and adoption hurdles; RGX-202’s accelerated-approval case rests on management-reported expression/function data and faces small-sample, safety, durability, manufacturing and immune-suppression risks.
Read full article (2 min)